BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Almehdi AM, Khoder G, Alchakee AS, Alsayyid AT, Sarg NH, Soliman SSM. SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. Infection 2021. [PMID: 34339040 DOI: 10.1007/s15010-021-01677-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Hamad M, AlKhamach DMH, Alsayadi LM, Sarhan SA, Saeed BQ, Sokovic M, Ben Hadda T, Soliman SSM. Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy. Viral Immunol 2023. [PMID: 36695729 DOI: 10.1089/vim.2022.0122] [Reference Citation Analysis]
2 Mohammad MG, Ashmawy NS, Al-Rawi AM, Abu-Qiyas A, Hamoda AM, Hamdy R, Dakalbab S, Arikat S, Salahat D, Madkour M, Soliman SSM. SARS-CoV-2-free residual proteins mediated phenotypic and metabolic changes in peripheral blood monocytic-derived macrophages in support of viral pathogenesis. PLoS One 2023;18:e0280592. [PMID: 36656874 DOI: 10.1371/journal.pone.0280592] [Reference Citation Analysis]
3 Yiang GT, Wu CC, Lu CL, Hu WC, Tsai YJ, Huang YM, Su WL, Lu KC. Endoplasmic Reticulum Stress in Elderly Patients with COVID-19: Potential of Melatonin Treatment. Viruses 2023;15. [PMID: 36680196 DOI: 10.3390/v15010156] [Reference Citation Analysis]
4 Suaifan GARY, Abu-Odeh AM, Shehadeh MB, Darwish RM, Shahwan M, Jbara FA. Knowledge, practice and attitude associated with SARS-CoV-2 Delta Variant among adults in Jordan. PLoS One 2022;17:e0278243. [PMID: 36477269 DOI: 10.1371/journal.pone.0278243] [Reference Citation Analysis]
5 Taffertshofer K, Walter M, Mackeben P, Kraemer J, Potapov S, Jochum S. Design and performance characteristics of the Elecsys anti-SARS-CoV-2 S assay. Front Immunol 2022;13:1002576. [PMID: 36532081 DOI: 10.3389/fimmu.2022.1002576] [Reference Citation Analysis]
6 Bouwmeester RN, Bormans EMG, Duineveld C, van Zuilen AD, van de Logt AE, Wetzels JFM, van de Kar NCAJ. COVID-19 vaccination and Atypical hemolytic uremic syndrome. Front Immunol 2022;13:1056153. [PMID: 36531998 DOI: 10.3389/fimmu.2022.1056153] [Reference Citation Analysis]
7 Wimalawansa S. Overcoming Infections Including COVID-19, by Maintaining Circulating 25(OH)D Concentrations Above 50 ng/mL. PLMI 2022;Volume 14:37-60. [DOI: 10.2147/plmi.s373617] [Reference Citation Analysis]
8 Li Y, Liu Z, Zeng M, El Kadiri A, Huang J, Kim A, He X, Sun J, Chen P, Wang TTY, Zhang Y, Gao B, Xie Z, Yu LL. Chemical Compositions of Clove (Syzygium aromaticum (L.) Merr. & L.) Extracts and Their Potentials in Suppressing SARS-CoV-2 Spike Protein–ACE2 Binding, Inhibiting ACE2, and Scavenging Free Radicals. J Agric Food Chem 2022;70:14403-14413. [DOI: 10.1021/acs.jafc.2c06300] [Reference Citation Analysis]
9 Dehghani J, Movafeghi A, Mathieu-Rivet E, Mati-Baouche N, Calbo S, Lerouge P, Bardor M. Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants. Mar Drugs 2022;20. [PMID: 36354980 DOI: 10.3390/md20110657] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sadraeian M, Zhang L, Aavani F, Biazar E, Jin D. Viral inactivation by light. eLight 2022;2:18. [DOI: 10.1186/s43593-022-00029-9] [Reference Citation Analysis]
11 Saifi S, Ravi V, Sharma S, Swaminathan A, Chauhan NS, Pandey R. SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength? Genomics 2022;114:110466. [PMID: 36041637 DOI: 10.1016/j.ygeno.2022.110466] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Meira C, Silva D, Santos I, Barreto B, Rocha V, Santos E, dos Reis B, Evangelista A, Ribeiro dos Santos R, Machado B, Ribeiro G, Badaró R, Soares M. Diagnostic Performance of Three ELISAs for Detection of Antibodies against SARS-CoV-2 in Human Samples. The Scientific World Journal 2022;2022:1-7. [DOI: 10.1155/2022/7754329] [Reference Citation Analysis]
13 Zappa M, Verdecchia P, Spanevello A, Angeli F. Structural evolution of severe acute respiratory syndrome coronavirus 2: Implications for adhesivity to angiotensin-converting enzyme 2 receptors and vaccines. Eur J Intern Med 2022:S0953-6205(22)00290-4. [PMID: 35985948 DOI: 10.1016/j.ejim.2022.08.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Taffertshofer K, Walter M, Mackeben P, Kraemer J, Potapov S, Jochum S. Design and Performance Characteristics of the Elecsys Anti-SARS-CoV-2 S assay.. [DOI: 10.1101/2022.07.04.22277103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Singh B, Avula K, Chatterjee S, Datey A, Ghosh A, De S, Keshry SS, Ghosh S, Suryawanshi AR, Dash R, Senapati S, Beuria TK, Prasad P, Raghav S, Swain R, Parida A, Hussain Syed G, Chattopadhyay S. Isolation and Characterization of Five Severe Acute Respiratory Syndrome Coronavirus 2 Strains of Different Clades and Lineages Circulating in Eastern India. Front Microbiol 2022;13:856913. [DOI: 10.3389/fmicb.2022.856913] [Reference Citation Analysis]
16 Bhosle SM, Tran JP, Yu S, Geiger J, Jackson JD, Crozier I, Crane A, Wada J, Warren TK, Kuhn JH, Worwa G. Duplex One-Step RT-qPCR Assays for Simultaneous Detection of Genomic and Subgenomic RNAs of SARS-CoV-2 Variants. Viruses 2022;14:1066. [DOI: 10.3390/v14051066] [Reference Citation Analysis]
17 Nabi-Afjadi M, Heydari M, Zalpoor H, Arman I, Sadoughi A, Sahami P, Aghazadeh S. Lectins and lectibodies: potential promising antiviral agents. Cell Mol Biol Lett 2022;27:37. [PMID: 35562647 DOI: 10.1186/s11658-022-00338-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Pierros V, Kontopodis E, Stravopodis DJ, Tsangaris GT. Unique peptide signatures of SARS-CοV-2 virus against human proteome reveal variants’ immune escape and infectiveness. Heliyon 2022. [DOI: 10.1016/j.heliyon.2022.e09222] [Reference Citation Analysis]
19 Neuberger M, Jungbluth A, Irlbeck M, Streitparth F, Burian M, Kirchner T, Werner J, Rudelius M, Knösel T. Duodenal tropism of SARS-CoV-2 and clinical findings in critically ill COVID-19 patients. Infection 2022. [PMID: 35182354 DOI: 10.1007/s15010-022-01769-z] [Reference Citation Analysis]
20 Mansy SS, AbouSamra MM. Electron microscopy overview of SARS-COV2 and its clinical impact. Ultrastruct Pathol 2022;:1-17. [PMID: 35139747 DOI: 10.1080/01913123.2022.2035475] [Reference Citation Analysis]
21 Demidkin S, Shwarts M, Chakravarty A, Joseph-mccarthy D. Machine Learning for the Identification of Viral Attachment Machinery from Respiratory Virus Sequences.. [DOI: 10.1101/2022.01.25.477734] [Reference Citation Analysis]
22 Singh B, Avula K, Chatterjee S, Datey A, Ghosh A, De S, Keshry SS, Ghosh S, Suryawanshi A, Dash R, Senapati S, Beuria TK, Prasad P, Raghav S, Swain R, Parida A, Syed GH, Chattopadhyay S. Isolation and Characterization of SARS-CoV-2 strains circulating in Eastern India.. [DOI: 10.1101/2021.12.13.472526] [Reference Citation Analysis]
23 Burkert FR, Lanser L, Bellmann-Weiler R, Weiss G. Coronavirus Disease 2019: Clinics, Treatment, and Prevention. Front Microbiol 2021;12:761887. [PMID: 34858373 DOI: 10.3389/fmicb.2021.761887] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
24 Treewattanawong W, Sitthiyotha T, Chunsrivirot S. Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor. Sci Rep 2021;11:22202. [PMID: 34772947 DOI: 10.1038/s41598-021-00684-x] [Reference Citation Analysis]
25 Kyosei Y, Namba M, Makioka D, Kokubun A, Watabe S, Yoshimura T, Sasaki T, Shioda T, Ito E. Ultrasensitive Detection of SARS-CoV-2 Spike Proteins Using the Thio-NAD Cycling Reaction: A Preliminary Study before Clinical Trials. Microorganisms 2021;9:2214. [PMID: 34835340 DOI: 10.3390/microorganisms9112214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Pierros V, Kontopodis E, Stravopodis DJ, Tsangaris GT. Unique Peptide Signatures Of SARS-CoV-2 Against Human Proteome Reveal Variants’ Immune Escape And Infectiveness.. [DOI: 10.1101/2021.10.03.462911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]